Previous 10 | Next 10 |
SAN DIEGO , April 29, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended March 31, 2019 and provided an update on the launch of INGREZZA ® (valbenazine) and its clinical development programs. ...
Portola Pharmaceuticals ( PTLA ) - The company announced that the European Commission granted conditional Marketing Authorization for Ondexxya (andexanet alfa) to be used in adult patients treated with the Factor Xa inhibitor apixaban or rivaroxaban when reversal of anticoagulation is needed...
Neurocrine Biosciences (NASDAQ: NBIX ) is scheduled to announce Q1 earnings results on Monday, April 29th, after market close. The consensus EPS Estimate is -$0.71 (-51.1% Y/Y) and the consensus Revenue Estimate is $136.77M (+92.4% Y/Y). Over the last 2 years, nbix has beaten EPS esti...
AKS , APTS , ARE , BRKS , BRX , CACC , CGNX , CHE , CHGG , CLR , CNI , CNO , CR , EPR , EQC , ETH , GHL , GOOG , HLIT , HTLF , INST , JBT , JJSF , KAI , LEG , LNTH , LOGI , MEDP , MGM , MKSI , MOH , MUSA , NBIX , NXPI , OGS , OII , OMF , PCH , PI , RG...
Neurocrine Biosciences ( NBIX -3.2% ) is down on almost triple normal volume in apparent response to Express Scripts' planned exclusion of tardive dyskinesia med Ingrezza (valbenazine), its sole marketed product in the U.S., from its formulary effective July 1. More news on: Neurocrine...
In February I wrote about Axovant Gene Therapies Ltd ( AXGT ), formerly Axovant Sciences ( AXON-OLD ), providing my thoughts on data expected in March 2019 from two of the company's trials, one in Parkinson's disease and one in GM2 gangliosidosis. I believed it was too early to recommend a l...
Neurocrine Biosciences (NASDAQ: NBIX ) initiated with Outperform rating and $113 (40% upside) price target at Evercore ISI. More news on: Neurocrine Biosciences, Inc., AcelRx Pharmaceuticals, Inc., Eli Lilly and Company, Healthcare stocks news, Stocks on the move, , Read more ...
SAN DIEGO , April 8, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report first quarter financial results after the Nasdaq market closes on Monday, April 29, 2019 . Neurocrine will then host a conference call and webcast to discuss its...
From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det...
SAN DIEGO and CAMBRIDGE, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR) today announced the publication of interim results from the Phase 1b trial of VY-AADC, an investigational gene therapy treatment for P...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...